Clinical Trial

A Study of LY3867070 in Healthy Participants

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate how well LY3867070 is tolerated and what side effects may occur in healthy participants. The study drug will be administered orally. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.
Protocol Amendment History 1 change
minor Trial arms changed: 6 -> 5 2026-05-23
Trial Details
NCT Number NCT07021547
Lead Sponsor Eli Lilly and Company
Conditions Healthy
Enrollment 196 participants
Start Date 2025-05-27
Primary Completion 2026-08 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2026-06-03